PRTK
Paratek Pharmaceuticals, Inc.PRTK
PRTK
Delisted
PRTK was delisted on the 20th of September, 2023.
About: Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Employees: 269
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference
BOSTON, May 16, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers that address important medical and public health threats, today announced that data from two clinical studies of NUZYRA® (omadacycline) will be presented at the ATS 2025 International Conference (ATS 2025), taking place in San Francisco, CA, May 16-21.
Neutral
GlobeNewsWire
1 month ago
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new studies of NUZYRA® (omadacycline) will be presented at ESCMID Global 2025, the Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Vienna, Austria, April 11-15. “We continue to invest in science as part of our commitment to furthering the medical community's understanding of NUZYRA,” said Randy Brenner, Chief Development and Regulatory Officer of Paratek.
Neutral
GlobeNewsWire
6 months ago
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that its U.S. supply and manufacturing capabilities for its novel antibiotic NUZYRA® (omadacycline) are now complete. NUZYRA is the company's broad-spectrum, novel antibiotic available in both intravenous and oral formulations approved by the U.S. Food and Drug Administration (FDA) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Neutral
GlobeNewsWire
6 months ago
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
First randomized placebo-controlled trial in NTM abscessus Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms Microbiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacycline In this 12-week study, omadacycline appeared to be safe and well-tolerated with no new or unexpected safety signals BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, today announced top-line results from its Phase 2b study of oral omadacycline in adult patients with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc). “The results from this first-ever placebo-controlled trial in MABc patients are exciting and support the idea that omadacycline has clinical utility in this very challenging disease setting.
Neutral
GlobeNewsWire
7 months ago
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that data from several new studies of NUZYRA® (omadacycline) will be presented at IDWeek 2024, Oct. 16-19 at the Los Angeles Convention Center in Los Angeles, CA. “We continue to invest in science as part of our continued commitment to furthering the medical community's understanding of NUZYRA's potential utility across a broad range of serious, community-acquired infections, including pulmonary and skin infections,” said Randy Brenner, chief development and regulatory officer of Paratek.
Neutral
GlobeNewsWire
10 months ago
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
- No Emergence of Resistance was Observed - Additional Years of Surveillance are Under Way BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today shared overall findings from the company's five-year post-approval microbiologic surveillance study of NUZYRA® (omadacycline), its broad-spectrum, oral and IV antibiotic. Surveillance studies are required by U.S. Food and Drug Administration (FDA) for all antibiotics as post-approval commitments and are intended to monitor for minimum inhibitory concentration (MIC) shifts as an indicator of potential resistance development.
Neutral
GlobeNewsWire
10 months ago
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade Label Update Discussions with FDA to Begin as Early as 4Q2024 BOSTON, July 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today released positive top-line results from a global, Phase 3 post-marketing commitment study comparing its once-daily oral and IV, broad-spectrum antibiotic NUZYRA® (omadacycline) to moxifloxacin in the treatment of patients with moderate to severe community-acquired bacterial pneumonia (CABP). Results from this double-blind study of moderate to severe CABP patients (n = 670 patients; PORT Risk Class III or IV) are consistent with findings from the pivotal Phase 3 study “Omadacycline for Pneumonia Treatment in the Community” (OPTIC; n = 774 adults; PORT Risk II, III, IV), which supported approval of NUZYRA for CABP by the U.S. Food and Drug Administration (FDA) and which was published in The New England Journal of Medicine in 2019.
Charts implemented using Lightweight Charts™